Mergers & Acquisitions - Roche, Pharmaceutical

Filter

Current filters:

RochePharmaceutical

Popular Filters

Roche said to be eyeing full control of Chugai

Roche said to be eyeing full control of Chugai

18-08-2014

Although the Swiss drug major has not issued a confirmation, media reports say Roche is close to acquiring…

Business FinanceChugai PharmaceuticalChugai Pharmaceutical Co.Chugai PharmaceuticalsHoffmann-La RocheInvestmentMergers & AcquisitionsPharmaceuticalRoche

Roche partners in new company for MS research

Roche partners in new company for MS research

23-06-2014

Swiss drug major Roche has entered into an exclusive partnership with Inception Sciences, a drug discovery…

Inception 5Inception SciencesMergers & AcquisitionsNeurologicalPharmaceuticalResearchRocheVersant Ventures

Roche to acquire Genia Technologies for up to $350 million

Roche to acquire Genia Technologies for up to $350 million

02-06-2014

Swiss drug major Roche said this morning that it plans to acquire Genia Technologies, a privately held…

Genia TechnologiesMergers & AcquisitionsPharmaceuticalRoche

Report: Life science companies experience IPO slowdown

10-12-2013

Life sciences companies have been completing fewer initial public offerings (IPOs) this season as the…

Mergers & AcquisitionsPharmaceuticalRocheSalix PharmaceuticalsShireUSA

July a strong month for life sciences IPOs and M&A

05-08-2013

The life sciences initial public offering (IPO) market continued to heat up in July as six life sciences…

BiotechnologyCubist PharmaceuticalsFinancialMergers & AcquisitionsPerrigoPharmaceuticalRoche

GlaxoSmithKline pulls sNDA for Tykerb plus Herceptin; Watson/Actavis update

13-07-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) revealed yesterday that it has withdrawn a supplemental New…

ActavisGenericsGlaxoSmithKlineHerceptinMergers & AcquisitionsNorth AmericaOncologyPharmaceuticalRegulationRocheTykerbWatson Pharmaceuticals

Amylin said to be attracting several Big Pharma suitors

16-05-2012

US biotech firm Amylin Pharmaceuticals (Nasdaq: AMLN), which earlier this year rebuffed a $22 per share…

AmylinAstraZenecaBiotechnologyBristol-Myers SquibbMerck & CoMergers & AcquisitionsPfizerPharmaceuticalRocheSanofiTakeda Pharmaceuticals

Roche will not extend its tender offer for Illumina

19-04-2012

In view of the apparent re-election of the incumbent directors of Illumina (Nasdaq: ILMN), a leading…

BiotechnologyIlluminaMergers & AcquisitionsPharmaceuticalRoche

Roche ratchets up the pressure on Illumina; analytical view

16-04-2012

If there is an axiom to describe Swiss drug major Roche (ROG: SIX), it is that what Roche wants, it gets,…

IlluminaMergers & AcquisitionsPharmaceuticalRoche

Roche presses on with takeover, despite further rejection by Illumina board

04-04-2012

Swiss drug major Roche (ROG: SIX), admitting disappointment that the board of Illumina (Nasdaq: ILMN)…

IlluminaMergers & AcquisitionsPharmaceuticalRoche

Roche ups bid for Illumina; M&A speculation on Amylin, Actavis

29-03-2012

There was a plethora of merger and acquisition news coming out yesterday and this morning, first of which…

ActavisAmylinBiotechnologyBristol-Myers SquibbGenericsIlluminaMergers & AcquisitionsMylan LaboratoriesPharmaceuticalRocheWatson Pharmaceuticals

Elan cashes in 76% chunk of its Alkermes stake for $381 million; Roche updates on Illumina bid

14-03-2012

Ireland-based Elan Corp (NYSE: ELN) revealed yesterday that it has raised around $381 million in net…

AlkermesElanElan Drug TechnologiesFinancialIlluminaMergers & AcquisitionsPharmaceuticalRoche

Roche has options beyond Illumina

07-03-2012

Speaking at the companys annual meeting, Swiss drug maj'or Roche (ROG: SIX) chairman Franz Humer said:…

FinancialIlluminaMergers & AcquisitionsPharmaceuticalRoche

Roche extends Illumina takeover deadline

28-02-2012

Roche has extended its $5.7 billion hostile takeover offer for genetic sequencing specialist Illumina…

HomeIlluminaMergers & AcquisitionsPharmaceuticalRoche

Riemser strengthens oncology range with Roche drug

15-02-2012

German drugmaker Riemser Arzneimittel AG is extending its range of supportive cancer therapy products…

Mergers & AcquisitionsOncologyOstacPharmaceuticalRiemser ArztneimittelRoche

Illumina board says Roche hostile bid “grossly inadequate”

08-02-2012

Having thoroughly reviewed Swiss drug and diagnostics major Roche’s (ROG: SIX) hostile takeover…

IlluminaMergers & AcquisitionsPharmaceuticalRoche

Illumina implements “poison pill” with regard to Roche bid

27-01-2012

Responding to Swiss drug major Roche’s (ROG: SIX) hostile takeover over offer of $44.50 per share…

IlluminaMergers & AcquisitionsPharmaceuticalRoche

Roche makes $5.7 billion hostile bid for Illumina

25-01-2012

Swiss drugs and diagnostic major Roche (ROG: SIX) announced this morning that it is proposing to acquire…

IlluminaMergers & AcquisitionsPharmaceuticalRoche

Roche in epigenetics drug discovery collaboration

18-01-2012

USA-based Constellation Pharmaceuticals says that it has entered into a major strategic agreement with…

BiotechnologyConstellation PharmaceuticalsGenentechLicensingMergers & AcquisitionsOncologyPharmaceuticalRoche

Roche acquires Verum Diagnostica for 11 million euros

05-12-2011

Swiss drugs and diagnostics major Roche (ROG: SIX) has signed an agreement under which it will acquire…

Mergers & AcquisitionsPharmaceuticalRocheVerum Diagnostica

Back to top